Leitlinien zur Therapie der akuten Manie

 

 Buy Article Permissions and Reprints

Zusammenfassung

Offizielle Therapieempfehlungen zur Therapie akuter Manien gibt es sowohl auf nationaler als auch auf internationaler Ebene. Sie werden auf der Basis der wissenschaftlichen Evidenz von einer Expertenkommission für die jeweiligen Psychopharmaka oder Therapiestrategien erstellt und in eine in der klinischen Praxis einsetzbare Form gebracht. Die World Federation of Societies of Biological Psychiatry (WFSBP) hat im Jahre 2003 solche Therapieempfehlungen publiziert. Sie geben einen Überblick über die relevanten Psychopharmakastudien zur akuten Manietherapie und zeigen einen Algorithmus auf, der sich an der Schwere der manischen Episode orientiert. Dabei gibt es vier Evidenzkategorien (A - D), die Auskunft über die Qualität der vorhandenen Studien geben.

Abstract

There are several national and international practice guidelines on the treatment of acute mania. Their purpose is to assess the available evidence of efficacy for medication used in the treatment of bipolar mania and to grade it according to the quality of studies available. The World Federation of Societies of Biological Psychiatry (WFSBP) has developed such guidelines in 2003. They categorize the scientific quality of the studies into four levels of evidence (A - D) and provide an algorithm based on the degree of severity of the acute manic episode.

Literatur

• 1 Suppes T, Dennehy E B, Swann A C, Bowden C L, Calabrese J R, Hirschfeld R M. et al . Report of the Texas Consensus Conference Panel on medication treatment of bipolar disorder 2000.  J Clin Psychiatry. 2002;  63 (4) 288-299
  PubMedGoogle Scholar
• 2 Licht R W, Vestergaard P, Kessing L V, Larsen J K, Thomsen P H. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark.  Acta Psychiatr Scand Suppl. 2003;  (419) 1-22
  PubMedGoogle Scholar
• 3 Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R W. et al . The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania.  World J Biol Psychiatry. 2003;  4 (1) 5-13
  PubMedGoogle Scholar
• 4 American Psychiatric Association . Practice guideline for the treatment of patients with bipolar disorder. (Revision).  Am J Psychiatry. 2002;  159 (4 Suppl) 1-50
  CrossrefPubMedGoogle Scholar
• 5 Bauer M S, Callahan A M, Jampala C, Petty F, Sajatovic M, Schaefer V. et al . Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs [see comments].  J Clin Psychiatry. 1999;  60 (1) 9-21
  PubMedGoogle Scholar
• 6 Bowden C L. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine.  Neuropsychopharmacology. 1998;  19 (3) 194-199
  PubMedGoogle Scholar
• 7 McElroy S L, Pope H GJ, Keck P E, Hudson G F, Phillips K A, Strakowski S M. Are impulse-control disorders related to bipolar diosrder?.  Compr Psychiatry. 1996;  (37) 229-240
  CrossrefPubMedGoogle Scholar
• 8 Poolsup N, Li-Wan P A, Olivera I R De. Systematic overview of lithium treatment in acute mania.  J Clin Pharm Ther. 2000;  25 139-156
  CrossrefPubMedGoogle Scholar
• 9 Freeman T W, Clothier J L, Pazzaglia P, Lesem M D, Swann A C. A double-blind comparison of valproate and lithium in the treatment of acute mania.  Am J Psychiatry. 1992;  149 (1) 108-111
  PubMedGoogle Scholar
• 10 Bowden C L, Brugger A M, Swann A C, Calabrese J R, Janicak P G, Petty F. et al . Efficacy of divalproex vs. lithium and placebo in the treatment of mania.  Journal of the American Medical Association. 1994;  271 (12) 918-924
  CrossrefPubMedGoogle Scholar
• 11 Pope H G, McElroy S L, Keck P E, Hudson J L. Valproate in the treatment of acute mania.  Arch Gen Psychiatry. 1991;  48 62-68
  PubMedGoogle Scholar
• 12 Emrich H M, Zerssen D von, Kissling W, Möller H J, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders.  Arch Psychiatr Nervenkr. 1980;  229 1-16
  CrossrefPubMedGoogle Scholar
• 13 Keck P E, McElroy S L, Tugrul K C, Bennett J A. Valproate oral loading in the treatment of acute mania.  J Clin Psychiatry. 1993;  54 305-308
  PubMedGoogle Scholar
• 14 Swann A C, Bowden C L, Calabrese J R, Dilsaver S C, Morris D D. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania.  Am J Psychiatry. 2000;  156 1264-1266
  PubMedGoogle Scholar
• 15 Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.  Int Clin Psychopharmacol. 1999;  14 (6) 339-343
  CrossrefPubMedGoogle Scholar
• 16 Tohen M, Sanger T M, McElroy S L, Tollefson G D, Chengappa K N, Daniel D G. et al . Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.  Am J Psychiatry. 1999;  156 (5) 702-709
  PubMedGoogle Scholar
• 17 Tohen M, Jacobs T G, Grundy S L, McElroy S L, Banov M C, Janicak P G. et al . Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group.  Arch Gen Psychiatry. 2000;  57 (9) 841-849
  CrossrefPubMedGoogle Scholar
• 18 Sachs G S, Grossman F, Ghaemi S N, Okamoto A, Bowden C L. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.  Am J Psychiatry. 2002;  159 1146-1154
  CrossrefPubMedGoogle Scholar
• 19 Yatham L N. Efficacy and tolerability of risperidone as combination therapy in bipolar mania: results from a randomised, double-blind study.  Eur Neuropsychopharmacol. 2000;  10 (Suppl 3) 250
  PubMedGoogle Scholar
• 20 Tohen M, Baker R W, Altshuler L L, Zarate C A, Suppes T, Ketter T A. et al . Olanzapine versus divalproex in the treatment of acute mania.  Am J Psychiatry. 2002;  159 (6) 1011-1017
  CrossrefPubMedGoogle Scholar
• 21 Bowden C L, Grunze H, Mullen J. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder.  J Clin Psychiatry. 2005;  66 111-121
  CrossrefPubMedGoogle Scholar
• 22 Keck P E, Ice K. Ziprasidone in acute mania. Abstract No 224. APA 2000
  Google Scholar
• 23 Keck Jr P E, Versiani M, Potkin S, West S A, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial.  Am J Psychiatry. 2003;  160 (4) 741-748
  CrossrefPubMedGoogle Scholar
• 24 Potkin S G, Keck P E, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized double-blind, placebo-controlled replication trial.  J Clin Psychiatry. 2005;  25 (4) 301-310
  PubMedGoogle Scholar
• 25 Licht R W. Drug treatment of mania: a critical review.  Acta Psychiatr Scand. 1998;  97 (6) 387-397
  PubMedGoogle Scholar
• 26 Weisler R H, Kalali A H, Ketter T A. SPD417 Study Group . A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.  J Clin Psychiatry. 2004;  65 478-484
  CrossrefPubMedGoogle Scholar
• 27 Weisler R H, Keck P E, Swann A C, Cutler A J, Ketter T A, Kalali A H. et al . Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.  J Clin Psychiatry. 2005;  66 (3) 323-330
  CrossrefPubMedGoogle Scholar
• 28 Keck P EJ, McElroy S L. Outcome in the pharmacologic treatment of bipolar disorder.  J Clin Psychopharmacol. 1996;  16 (2, Suppl 1) 15S-23S
  PubMedGoogle Scholar
• 29 Emilien G, Maloteaux J M, Seghers A, Charles G. Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis.  Eur Neuropsychopharmacol. 1996;  6 245-252
  CrossrefPubMedGoogle Scholar
• 30 Post R M, Ketter T A, Denicoff K, Pazzaglia P J, Leverich G S, Marangell L B. et al . The place of anticonvulsant therapy in bipolar illness.  Psychopharmacology. 1996;  128 115-129
  CrossrefPubMedGoogle Scholar
• 31 Hesslinger B, Normann C, Langosch J M, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.  J Clin Psychopharmacol. 1999;  19 310-315
  CrossrefPubMedGoogle Scholar
• 32 Mukherjee S, Rosen A M, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients.  Arch Gen Psychiatr. 1986;  43 (4) 342-346
  PubMedGoogle Scholar
• 33 Swann A C, Bowden C L, Calabrese J R, Dilsaver S C, Morris D D. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania.  Neuropsychopharmacology. 2002;  26 (4) 530-536
  CrossrefPubMedGoogle Scholar
• 34 Secunda S K, Swann A, Katz M M, Koslow S H, Croughan J, Chang S. Diagnosis and treatment of mixed mania.  Am J Psychiatry. 1987;  144 (1) 96-98
  PubMedGoogle Scholar
• 35 Himmelhoch J M, Garfinkel M E. Sources of lithium resistance in mixed mania.  Psychopharmacology Bulletin. 1986;  22 (3) 613-620
  PubMedGoogle Scholar
• 36 Goldberg J F, Garno J L, Leon A C, Kocsis J H, Portera L. Rapid titration of mood stabilizers predicts remission from mixed or pure mania in bipolar patients [published erratum appears in J Clin Psychiatry 1998 Jun; 59 (6): 320].  J Clin Psychiatry. 1998;  59 (4) 151-158
  PubMedGoogle Scholar
• 37 Benabarre A, Vieta E, Colom F, Martinez A, Reinares M, Corbella B. Treatment of mixed mania with risperidone and mood stabilizers.  Can J Psychiatry. 2001;  46 (9) 866-867
  PubMedGoogle Scholar
• 38 Whitlock F A, Evans L E. Drugs and depression.  Drugs. 1978;  15 53-71
  PubMedGoogle Scholar
• 39 Coryell W, Leon A C, Turvey C, Akiskal H, Mueller T I, Endicott J. The significance of psychotic features in manic episodes: a report from the NIMH collaborative study.  J Affect Disord. 2001;  67 (1 - 3) 79-88
  CrossrefPubMedGoogle Scholar
• 40 Johnstone E C, Crow T J, Frith C D, Owens D G. The Northwick Park „functional psychosis” study: diagnosis and treatment response.  Lancet. 1988;  2 119-125
  CrossrefPubMedGoogle Scholar
• 41 Kusumakar V, Lakshmi N Y, Haslam D RS, Parikh S V, Matte R. Treatment of mania, mixed state and rapid cycling.  Canadian Journal of Psychiatry. 1997;  42 (Suppl 2) 79S-86S
  PubMedGoogle Scholar
• 42 McElroy S L, Keck P E, Stanton S P, Tugrul K C, Bennett J A, Strakowski S M. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.  J Clin Psychiatry. 1996;  57 (4) 142-146
  PubMedGoogle Scholar
• 43 Akiskal H. Dysthymia and cyclothymia in psychiatric practice a century after Kraepelin.  J Affect Disord. 2001;  62 31
  PubMedGoogle Scholar
• 44 Deltito J A. The effect of valproate on bipolar spectrum temperamental disorders.  J Clin Psychiatry. 1993;  54 300-304
  PubMedGoogle Scholar
• 45 Jacobsen F M. Low-dose valproate: a new treatment for cyclothymia, mild rapid cycling disorders and premenstrual syndrome.  J Clin Psychiatry. 1993;  54 229-234
  PubMedGoogle Scholar
• 46 Vieta E, Gasto C, Colom F, Reinares M, Martinez-Aran A, Benabarre A. et al . Role of risperidone in bipolar II: an open 6-month study.  J Affect Disord. 2001;  67 (1 - 3) 213-219
  CrossrefPubMedGoogle Scholar
• 47 Amann B, Schlösser S, Sterr A, Hummel B, Schäfer M, Padovan C S. et al . Anticonvulsants in the treatment of aggression in the demented elderly.  Psychiatric Networks. 2000;  3 87-95
  PubMedGoogle Scholar
• 48 Small J G, Klapper M H, Kellams J J, Miller M J, Milstein V, Sharpley P H. et al . Electroconvulsive treatment compared with lithium in the management of manic states.  Arch Gen Psychiatry. 1988;  45 727-732
  PubMedGoogle Scholar
• 49 Black D W, Winokur G, Nasrallah A. Treatment of mania: a naturalistic study of electroconvulsive therapy versus lithium in 438 patients.  J Clin Psychiatry. 1987;  48 132-139
  PubMedGoogle Scholar
• 50 Mukherjee S, Sackeim H A, Schnur D B. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience.  Am J Psychiatry. 1994;  151 169-176
  PubMedGoogle Scholar

Dr. med. Heinz Grunze

Klinik und Poliklinik für Psychiatrie der Ludwig-Maximilians-Universität München

Nußbaumstraße 7

80336 München

Email: heinz.grunze@med.uni-muenchen.de